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The Affymetrix GeneChip® Canine Genome 2.0 microarray is re-annotated using 
AgBase tools, up-to-date ID mapping and GO annotations associated with publicly 
available gene products updated on this array. This re-annotation makes the array more 
useful for researchers using the canine microarray for biological discovery. We use flow 
cytometry to determine if liposomal clodronate (LC) is an acceptable alternative to 
surgical splenectomy to facilitate detection of subclinical infection with Babesia canis in 
potential blood donor greyhounds. Our study shows that LC is not a reliable means of 
exposing babesiosis in greyhounds with a recent history of infection.  We evaluate the 
effect of depletion of antigen presenting cells on regulatory T cells (Tregs) in dogs treated 
with LC by multi-color flow cytometry. We demonstrate that LC promotes increases in 
the CD4+CD25+FOXP3+ Tregs affecting mostly the CD4+CD25lowFOXP3+ Tregs subset 
suggesting a role of monocytes in naïve T cell priming and differentiation into Tregs. 
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There is an ongoing movement to utilize high-throughput functional genomics 
platforms to derive biologically significant information from lists of numerous identifiers 
and accessions. In addition, there is a need for up-to-date accessions to facilitate data 
availability and ease of use for various fields of research. The canine model, which is 
used in several areas of medical research, has the potential to provide translational 
information to promote medical research if data are readily available. 
Babesia is an intracellular protozoan parasite that exploits red blood cells (RBCs). 
It is the causative agent of babesiosis, which is not only considered an emerging disease 
in the U.S., but is also a major concern in veterinary practice. Disease caused by Babesia 
canis is commonly subclinical in greyhounds, which, in turn, become chronic carriers. As 
the most common blood donors used in veterinary medicine, greyhounds must be 
screened for Babesia to prevent a parasite transmission from blood donors to recipients 
that could develop potentially fatal babesiosis. In the past, screening of potential blood 
donors was performed using a surgical splenectomy to reveal circulating protozoa. As the 
spleen is responsible for removing infected RBCs, absence of the spleen will lead to 
observable parasitemia indicating that the animal is unfit to join the blood donor pool. 
However, this invasive practice has dropped out of favor, because it leaves the animal 
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permanently immune-suppressed. Here, we explore the possibility of a medical 
splenectomy utilizing liposome encapsulated clodronate. 
Liposomal clodronate (LC) is used to cause transient immune suppression in both 
research and clinical settings by depleting monocytes, macrophages and immature 
dendritic cells (DCs) via apoptosis. Here, greyhounds exposed to Babesia were treated 
with differing levels of LC and Babesia infected RBC numbers were evaluated via flow 
cytometric analysis over the course of treatment. We propose that LC treatment could be 
an alternative to surgical splenectomy for potential blood donors. 
Also, for the first time, regulatory T cell (Tregs) numbers were evaluated in the 
absence of professional antigen presenting cells (APCs), monocytes, macrophages and 
immature DCs. Tregs are a subset of T cells defined as CD4+CD25+FOXP3+, and that are 
critical for suppression and regulation of normal canine immune responses. Canine Tregs 
are poorly understood, but new staining techniques provide a key to unearthing much 
needed information on this critical cell type. 
Three specific aims accomplished in this thesis research are as follows: 
Functional Annotation of the Affymetrix GeneChip® Canine Genome 2.0 
Microarray 
Hypothesis: By re-annotating the Affymetrix Canine Genome 2.0 microarray, we 
will increase the number of annotations provided for the microarray as a 
whole and the quality of annotations provided for the array. 
Objective: To improve the existing functional annotation of the Affymetrix 
Canine Genome 2.0 microarray. 
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To achieve this objective: A digital file including all Affymetrix probeset 
identifiers on the microarray was re-annotated and updated using AgBase 
tools. This updated information was made publicly available in a user-
friendly format at the Mississippi State University Agbase website. 
Use of liposomal clodronate (LC) to facilitate detection of subclinical Babesia canis 
infection in potential blood donor greyhounds 
Hypothesis: Transient immune suppression by liposomal clodronate (LC) will 
facilitate detection of subclinical Babesia canis infection in potential 
canine blood donors. 
Objective: Evaluate the role of liposomal clodronate in the development of 
parasite infection in erythrocytes of greyhounds with known exposure to 
Babesia canis (PCR and anti-Babesia antibody positive) but without 
evidence of productive Babesia infection in their red blood cells (flow 
cytometry and blood smear negative). 
To achieve this objective: Four greyhounds with a history of varying levels of 
positivity for exposure/confirmed presence of Babesia were given a low, 
medium, and high dose of liposomal clodronate.  To evaluate the effect of 
the drug, the levels of parasite-infected red blood cells in peripheral blood 
was measured using specific single color flow cytometric analysis and 
results analyzed by one-way ANOVA statistics. 
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The effects of selective LC-dependent removal of professional antigen presenting 
cells (APCs), monocytes, macrophages and immature dendritic cells (DCs) on  
the numbers and phenotypes of CD4+CD25+FOXP3+ regulatory T cells 
Hypothesis: Monocytes/macrophages and immature DCs are the major APC 
populations shaping protective adaptive immune responses in dogs, as has 
been demonstrated in humans and mice, and their impaired function leads 
to immune suppression through a conversion of naïve T cells into 
suppressive FOXP3-expressing Tregs. 
Objective: Evaluate the role of professional APCs (monocytes/macrophages/DCs) 
in the generation of FOXP3-expressing regulatory T cells in normal dogs 
and dogs exposed to Babesia canis. 
To achieve this objective: The numbers of Tregs in four greyhounds previously 
exposed to Babesia canis were assessed following the administration of 
low, medium, and high doses of liposomal clodronate. The numbers and 
phenotypes of Tregs and the levels of CD14+ monocytes of four normal 
Walker hounds treated with the medium dose of LC, and Tregs were 
observed. For both studies, multiple color flow cytometric analysis was 




REVIEW OF PERTINENT LITERATURE 
Microarray and Gene Ontology 
The use of microarrays in research generates a large amount of data that must be 
translated into biologically relevant information. In order to accomplish this, researchers 
use annotation, the practice of attaching biological information to sequences. This 
information can then be interpreted by researchers themselves or entered into modeling 
tools such as pathway analysis and Gene Ontology(GO) enrichment tools [1]. There are 
two components of annotation: structural annotation and functional annotation. Structural 
annotation is the identification of demarcation of the genomic boundaries of individual 
functional elements within the genome sequence and includes providing accessions and 
identifiers for commonly used public databases. This tends to occur as the genome 
sequence is assembled and continues as new information is acquired. Functional 
annotation associates a gene product’s functional information with the gene product itself 
and is not commonly done during genome sequencing [1, 2]. GO has become the 
standard for functional annotation. It is a structured network consisting of defined terms 
and relationships between them that describe three attributes of gene products: molecular 
function, biological process, and cellular component [3]. These three independent 
ontologies are dynamic and while having a common language, they exist in a network 
that changes constantly as more information is acquired [4]. Using GO annotation, 
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researchers can take large amounts of data generated from microarrays and assign 
biological significance to their results based on the function, process, or component they 
are associated with. Researchers spend large amounts of time and money to annotate their 
singular dataset. In this project, we sought to re-annotate the Affymetrix Canine Gene 
Chip 2.0 microarray that was annotated in 2006.  As information content of databases 
such as GO keeps changing, there is a need for re-annotation of microarrays and 
dissemination of this updated information to the public. The end result is improved ability 
to perform analysis of canine samples. 
Liposomal Clodronate 
Clodronate or dichloromethylene-bisphosphonate is being used in various types of 
treatments and experiments in many different fields of the scientific and medical 
communities [5]. When taken into professional phagocytes, including both DCs and 
monocytes/macrophages, clodronate is metabolized to adenosine 5’ triphosphate with the 
end result being the lysis of the mitochondrial membrane within the host 
monocytes/macrophage, which leads to the induction of apoptosis [6, 43], therefore 
depleting the number of viable monocytes/macrophages and DCs that are available for 
immune response. A recent study, however, has argued that clodronate causes cell death 
via necrosis rather than apoptosis as previously reported [7]. If that is the case, the 
cytotoxicity of clodronate could very well cause adverse effects in local tissues when 
released at cell lysis. 
When administered as a free pharmaceutical, bisphosphonates such as clodronate 
are considered to be “bone-seeking molecules” [7], and only very small amounts of the 
drug are taken up via phagocytosis. Thus, the resulting intracellular concentrations are 
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too small to induce the most often desired apoptosis [5]. In order to circumvent this, 
clodronate is often administered in the liposome encapsulated formation. This prolongs 
the amount of time the molecule spends in circulation and increases the chance of 
phagocytosis by professional phagocytes [7]. In instances when the immune response 
may be detrimental to the overall health of the patient, clodronate is one way that we may 
suppress both the innate and adaptive responses. 
Liposomes are tiny vesicles composed of one or more concentric phospholipid 
bilayers, and they have been found to be efficient methods of delivering water soluble 
drugs to phagocytes [5]. Size and charge of the liposome are important characteristics to 
take into consideration when developing treatments or experiments. It has been found 
that the optimal liposome is negatively charged and has a size of 85±20nm.  If too large, 
the particle runs the risk of inducing the production of pro-inflammatory cytokines such 
as IL-6, TGF-α, and IL-1β that can cause further damage when treating conditions such 
as autoimmune diseases. If too small, they can have no effect at all [7]. 
Liposomes are known to enhance phagocytosis in monocytes/macrophages, but 
there are at least two conditions that must be met in order for the encased clodronate to 
induce apoptosis in these cells. First, the phagocytosis of a liposome-encased clodronate 
is not enough to ensure apoptosis. There are many cell types that will take in this 
molecule, but the cells must also have the mechanisms required to lyse the liposomal 
membrane to release the clodronate contents. Second, the intracellular concentration of 
clodronate must reach a threshold. If the concentration is too low, apoptosis may not 
occur. In one study, activated monocytes were observed to have higher levels of 
phagocytosis and therefore had higher levels of associated apoptosis when compared to 
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resting or non-activated monocytes. Overall, the intracellular concentration of clodronate 
regulates the cytotoxic effects or degree of cell death achieved by a single dose of 
liposome-encased clodronate [5]. 
Many scientists are using liposome-encased clodronate to deplete the numbers of 
monocytes/ macrophages and DCs in the course of an immune response for many 
different types of experimental studies. LC has been used to provide controls for 
experiments evaluating the role of monocytes and macrophages in muscle injury [8] and 
even in diseases such as acute gout [9]. LC is being used to treat various autoimmune 
diseases due to its selective targeting of disease-related monocytes and macrophages [5], 
and it has been used in the study of dengue fever to prove that monocytes and 
macrophages are critical elements in controlling the virus [10]. In 2004, a study showed 
that by depleting monocytes and macrophages by administration of liposome-encased 
clodronate, hyperalgesia was decreased in part due to the decrease in pro-inflammatory 
mediators produced by those cell types [6]. However, when administering liposomal 
clodronate systemically, there is not a significant amount of monocytes/macrophage 
depletion in specific sites. In these cases where a specific tissue is being evaluated, direct 
local injections are effective in lowering monocyte/ macrophage numbers for several 
days. Depletion percentages for circulating monocytes/macrophages have been reported 
as high as 70%, and for certain populations of monocyte-derived tissue macrophages has 
been anywhere from 15-60% [6]. 
In 2005, a method utilizing LC’s macrophage depletion characteristics was 
developed that allowed for the acceleration of alveolar macrophage reconstitution [11]. 
Also, LC has been used to decrease the instance of dissemination and brain invasion by 
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Cryptococcus neoformans. The causative agent of cryptococcosis, Cryptococcus 
neoformans is thought to use monocytes as a type of “Trojan horse” that can carry it to 
various organs including the spleen and lungs and even across the blood brain barrier 
[12]. Another study describes how the act of depleting macrophages can generally be 
both good and bad. It exacerbates early aortic lesions allowing for increase in collagen 
content which can cause a widening or growth to be observed. On the other hand, the 
depletion of macrophages does decrease the production of pro-inflammatory cytokines as 
previously stated [13]. 
All in all, encapsulation inside liposomes enhances the effectiveness of clodronate 
as an immune response inhibitor. Liposome-encased clodronate has widespread uses in 
both research and treatment, but should be selected for use on a case-by-case basis. It has 
both beneficial effects as well as adverse effects, and those must be weighed carefully. 
Babesia 
Babesia canis is an intracellular protozoan parasite carried by ticks, in particular 
Rhipicephalus sanguineus ( the brown dog tick), which invades canine red blood cells 
(RBCs). Transmission from tick to canine host is complete after a 2-3 day feeding 
attachment by the tick [14, 15]. Once in the canine host circulatory system, the organism 
attaches to RBCs and is internalized via endocytosis [16]. Once in the cytoplasm of the 
host’s RBCs, then the organism is free to reproduce via binary fission resulting in rupture 
of current RBC and infection of local RBCs [14].  
It is known that Rhipicephalus sanguineus transmits the causative agent of canine 
babesiosis in greyhounds in the United States. Babesia canis subspecies vogeli, and 
disease caused by this protozoan has been recognized in greyhound kennels [14]. 
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Greyhounds are the most commonly used blood donors in veterinary medicine, because a 
high percentage of the breed are universal blood donors, have high hematocrits, gentle 
dispositions, and easy to access jugular veins [17]. Greyhounds and their propensity for 
babesiosis causes concern in blood transfusion recipients, because a transfusion with 
Babesia-infected blood commonly leads to potentially devastating babesiosis. In donor 
recipients of Babesia-infected blood, severe babesiosis can lead to multiple organ 
dysfunction syndromes, septic shock, or even death [14, 18]. In puppies or adult dogs, 
babesiosis can often develop alongside a secondary disease. These cases are often 
characterized by fever, lethargy, anorexia and jaundice. Clinically, evidence may indicate 
hemolytic regenerative immune-mediated anemia, leukocytosis, and thrombocytopenia 
[19, 20, 14]. In greyhounds, it is often hard to diagnose babesiosis since it is most 
commonly a mild infection with non-specific clinical signs, and affected dogs can 
become chronic sub-clinical carriers [18].  
Accepted methods for detection of babesiosis include microscopic identification 
of the organism on fresh blood smears, serologic testing using an IFA (indirect 
fluorescent antibody test), PCR (polymerase chain reaction) assay targeting the Babesia 
spp. small subunit ribosomal RNA (ribonucleic acid) gene in the blood, and flow 
cytometric evaluation of RBCs [14].There are limitations to some of these tests. Blood 
smears utilizing Giemsa stains are not sensitive tests for detecting Babesia, because it is 
hard to visualize the organism unless a moderate to high parasitemia is present [14, 21]. 
When running antibody tests such as IFA, it can be hard to distinguish active infection 
from one that has already cleared due to the persistence of antibodies within the host’s 
immune system [18, 22]. Flow cytometry also relies on a detectable parasitemia. In 
 
11 
instances where tests are positive, donors must be rejected to prevent possible 
repercussions due to transfusions with infected blood. Although PCR is a definitive test 
for Babesia canis, this is not a technique most clinics have quick and easy access to, and 
PCR positivity alone does not permit quantitation of the number of infected RBCs. For 
this thesis research, the focus turned to flow cytometric analysis. Several methods for 
quantifying red blood cells infected with Babesia via flow cytometry have been 
successful: the use of HE (hydroethidine) in DMSO (dimethyl sulfoxide) for staining was 
utilized here [22, 23]. 
Regulatory T cells 
Although they are well documented in human and murine research, little is known 
about the functional significance of regulatory T cells (Tregs) in the canine. However, it 
is apparent that Tregs are an important constituent of healthy function of the host immune 
system. Tregs may be either thymus-derived naturally occurring Tregs or Tregs that are 
induced in the periphery from conventional peripheral CD4+ T cells [24, 25]. Regulatory 
T cells are responsible for maintaining tolerance and preventing autoimmunity by 
retaining the ability to suppress the activation and function of effector T cells and antigen 
presenting cells (APCs) via their suppressive actions, which include both direct and 
indirect suppression. Direct suppression used against effector T cells can be considered 
an activation-dependent process, but requires cell-cell interactions in order actively 
suppress effector T cells [26]. On the other hand, indirect suppression, in evidence versus 
APCs, includes induction of the enzyme IDO (indoleamine 2,3-dioxygenase) which 




In normal systems, when activated or increased in numbers to a suitable 
concentration, Tregs can help to prevent autoimmune dysfunction of the host system [31, 
33], or they may exacerbate any ongoing pathology [32, 34, 35, 36, 37, 38, 39]. Although 
more research is needed, studies have shown that a nuclear transcription factor FOXP3 
(forkhead box P3 transcription factor) is necessary for the natural generation of naïve T 
cells into regulatory T cells with suppressive functions. Without FOXP3, the 
recognizable immunosuppressive function can be lost [27, 28, 29]. Currently, it has been 
shown that conventional T cells stimulated via antigen in the presence of essentials such 
as TGF-β, IL-10, and retinoic acid will be induced to Tregs [40, 41, 42]. 
There is still much research to be performed in order to comprehensively detail 
the function of Tregs and their role in the canine immune response, but studies are 
beginning to show that functions of Tregs in canines are similar to known functions 
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FUNCTIONAL ANNOTATION OF THE AFFYMETRIX CANINE 2.0 
MICROARRAY 
Abstract 
Researchers using high-throughput functional genomics platforms such as 
microarrays must be able to derive biologically relevant insights from the results, which 
are returned as lists of numerous identifiers and accessions. This is a problem due to the 
amount of time and resources needed to turn those accessions into applicable data. The 
lack of functional annotation associated with arrays is also a challenge for modeling array 
data. Despite an increase in the amount of canine genomics research, the annotation files 
provided for the Affymetrix GeneChip® Canine Genome 2.0 microarray contain 
functional annotations for only 14.5% of transcripts represented on this array. We re-
annotated the Affymetrix canine array, providing updated database identifiers and new 
functional annotations. Here we linked the Affy probe IDs to identifiers from commonly 
used databases to create an ID mapping file which can be used to facilitate data sharing 
between differing databases. In addition, we linked these same gene products to existing 
functional annotation using the Gene Ontology (GO), and provided new GO annotation 
where none existed. After remapping, we identified 10,737 existing GO annotations for 
5,127 of the newly mapped gene products represented on the array. In addition, we added 
70,148 annotations for 16,966 gene products. Thus, we have provided annotations for 
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94% of this array, which represents a seven-fold increase in the number of gene products 
than were originally annotated. The resultant data is publicly available at the AgBase 
website (http://agbase.msstate.edu) and will be periodically updated during standard 
database updating procedures. The new data provided enables canine researchers to more 
efficiently functionally model their Affymetrix array datasets and translate array data into 
additional knowledge. 
Background 
The canine genome was initially released in July 2004 by the BROAD Institute’s 
Dog Genome Project, and then a new version was released in May 2005 [4, 5]. A 
commonly used canine microarray, the Affymetrix GeneChip® Canine Genome 2.0 
(GPL: 3738), with probes for over 18,000 canine mRNA/EST transcripts and over 20,000 
non-redundant predicted genes, was designed to help obtain biologically relevant 
information from this genome (6). The identifier mappings and GO annotations 
associated with this array were last updated in 2006 [7].  
The outdated or lack of functional annotations associated with microarrays 
hinders researchers who wish to model their array data results to obtain biologically 
relevant information. Thus, despite the importance of canine array research, only 5% of 
available datasets generated using this array have been published, while only 4% of 
available datasets have been published for all canine array platforms (based on Gene 
Expression Omnibus database, 2/2013), Figure 3.1. This represents thousands of dollars 
of research that has not yet been translated to biological relevance for biomedical and 
veterinary research. Moreover, these figures are likely to under-represent the magnitude 
of the problem, because not all datasets from canine array research will have been 
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submitted as researchers try to obtain annotations. However, re-annotation of arrays with 
the most up-to-date functional annotations can lead to significant changes in the 
interpretation of array datasets [8]. 
 
Figure 3.1 Estimation of data generated using canine assays.  
Representative of canine datasets in GEO as of 2/2013. 
Annotation is the practice of attaching biological information to sequences, and it 
is this information that is used not only by researchers but also by functional modeling 
tools such as pathways analysis and Gene Ontology (GO) enrichment analysis tools. 
There are two components of annotation: structural annotation and functional annotation. 
Structural annotation is the identification of individual functional elements within the 
genome sequence and includes providing accessions and identifiers for commonly used 
public databases. This is generally initiated as the genome sequence is assembled and 
continues on-going as new information is acquired. Functional information, alternatively, 
associates a gene product’s functional information with the gene product itself and is not 
commonly performed during genome sequencing [1].   
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GO has become the standard for functional annotation, and is a structured 
network consisting of defined terms and relationships between them that describe three 
attributes of gene products: Molecular Function, Biological Process, and Cellular 
Component [2]. These three independent ontologies are dynamic and while having a 
common language, they exist in a network that changes constantly as more information is 
acquired [3]. 
To make functional modeling in canine research more accessible for researchers, 
we re-annotated the largest and most frequently used microarray, the GeneChip® Canine 
Genome 2.0 Array from Affymetrix. This updated array annotation will be made publicly 
available at AgBase at http://www.agbase.msstate.edu. 
Methods 
Affymetrix Array Files and Array Statistics 
The Affymetrix GeneChip® Canine Genome 2.0 (GEO platform accession GPL: 
3738) has probes that represent 18,000 canine mRNA/EST transcripts and over 20,000 
non-redundant predicted genes. We obtained canine array dataset numbers from the Gene 
Expression Omnibus (GEO) database (http://www.ncbi.nih.gov/geo) using specific 
searches (Figure 3.1). The number of canine datasets submitted was obtained using the 
search criteria: dog[organism]. The number of those datasets that were linked to 
publications was obtained using the refined search criteria: dog[organism] AND “gds 
pubmed”[filter]. The number of datasets submitted from only the Affymetrix GeneChip® 
Canine Genome 2.0 array, was obtained using search criteria: GPL3738. The number of 
those datasets that were linked to publications was obtained by the refined search criteria: 




Since different functional modeling tools often require different public database 
accessions or identifiers, accession mapping of Affy probe IDs to multiple public 
databases was done to provide an up-to-date, comprehensive cross-mapping file to 
support functional modeling. The ArrayIDer tool is available for public use and can be 
accessed via the AgBase website. This tool accepts numerous ID types, including 
Affymetrix probeset identifiers which result from the use of Affymetrix microarrays. A 
document is then generated by the tool which matches these probeset identifiers to a list 
of equivalent identifiers used by other publically available databases such as UniProtKB, 
Ensembl, RefSeq, and Entrez Gene. ID types preferred were UniProtKB (Universal 
Protein Knowledgebase) and RefSeq, with UniProtKB identifiers desired due to their 
high-quality manual annotations. Ensembl, RefSeq, and Entrez identifiers were mapped 
back to any corresponding UniProtKB and RefSeq protein identifiers using the publically 
available BioMart application provided by the Ensembl website [7]. All RefSeq protein 
identifiers were then checked against the National Center for Biotechnology Information 
(NCBI) database to update this list of identifiers with any revisions or deletions. Updated 
RefSeq protein identfiers were then mapped to UniProt identifiers using the publically 
available ID Mapping application [8]. These updated identifiers were compiled into a 
single ID Mapping file that is available online at the AgBase Array Annotation section. 
Figure 3.2 outlines the workflow of re-mapping and re-annotating the GeneChip® Canine 




Figure 3.2 Workflow schematic showing the process of ID mapping and linking GO 
annotation. 
Functional annotation begins by accession mapping through ArrayIDer which divides the 
input file into broad categories: ESTs, BROAD, Entrez, Ensembl, UniProKB, Genbank 
RefSeq. UniProtKB and Genbank RefSeq are sent through GORetriever which pulls 
existing GO annotations while the rest undergo manual biocuration. ESTs, BROAD, and 
Entrez accessions go through sequence analysis of functional motifs and domains. 
GO Annotation 
Since a key step in functional modeling is GO enrichment analysis, canine gene 
products from the ID Mapping file were linked to GO annotations. Currently, there is no 
dedicated GO annotation for dog gene products and the main source of existing GO 
annotation are the UniProtKB annotations provided by the EBI GOA Project [1]. We 
used the ID mapping file to identify any array probes that had a mapping to UniProtKB 
and used GORetriever [2] to get these annotations. Next we provided GO annotations for 
the remaining gene products represented on the array based on their type of database 
accession (which indicates the type of data available for the corresponding gene product). 
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Expressed Sequence Tags (ESTs): Since there is no experimental functional data 
available for ESTs, these sequences can only be GO annotated based upon sequence 
analysis of functional motifs and domains [9]. EST sequences identified form the canine 
microarray were downloaded from the dbEST, prepared as FASTA files and this data was 
submitted to the InterProScan program [3]. The resulting InterPro identifiers were 
mapped to GO using the InterPro2GO mapping file [4]. These annotations are given the 
GO evidence code “Inferred from Electronic Annoation” (IEA) and provide broad 
functional information that can be used to predict function and support hypothesis testing. 
BROAD: These identifiers are associated with the BROAD Institute of MIT and 
Harvard and the canine genome project. Retrieving annotations for this subset of 
identifiers is still currently ongoing. Updated annotations will be added to the publically 
available files as they are retrieved. 
UniProtKB and RefSeq Identifiers: Using the GORetriever tool that is provided to 
the public by AgBase [2], all existing GO annotation for probes on the microarray 
associated with UniProtKB and RefSeq identifiers were separately annotated through 
critical analysis of experimental data of published literature using Gene Ontology 
Consortium (GOC) guidelines. The resulting compilation of updated GO annotations for 
all gene products associated with the Affymetrix GeneChip® Canine 2.0 microarray were 
compiled into a single file and will be made publicly available at the AgBase website in 
the Array Annotations section after quality check is done using GOC guidelines [6]. 
GAQ Score 
The GO Annotation Quality (GAQ) Score [5] measures the breadth of GO 
annotation, the level of detail of the annotation, and the type of evidence used to make the 
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annotation to provide a quantitative measure of the overall quality of the GO annotations. 
All updated anntoations retrieved were combined into a single file that was arranged into 
the gene associated file format 2.0, and then uploaded into the AgBase tool in a delimited 
form. Output form this tool provides a summary containing the total GAQ score, the 
number of non-redundant gene products, and the mean GAQ. 
Results and Discussion 
Since functional annotation is continually changing as more data is added, to 
derive biologically relevant functional information from arrays, scientists need ready 
access to the most up-to-date annotation. Although microarrays are used to study canine 
systems, only a small fraction of the data is published [Figure 3.1]; this lack of functional 
annotation is hindering biological modeling of this data. For example, the Affymetrix 
canine microarray was last annotated in May 2006, although it represents 36% of datasets 
submitted in GEO. Our re-annotation provides increased amounts of functional 
information and shows that the overall quality of this annotation has also increased. 
Moreover, we provide annotated data in a format that will facilitate functional analysis 
and make it publicly available for GO enrichment analysis tools. 
The Affymetrix GeneChip® Canine Genome 2.0 microarray (GPL:3738) contains 
over 18,000 probesets which represent over 20,000 gene products [10,11]. Prior to 
remapping, the original 18,342 unique probeset identifiers from the array were mapped to 
a total of 26,818 unique identifiers and accessions from UniProtKB, RefSeq, and 
Ensembl which are commonly used public databases. Since each probeset is mapped to 
its equivalent accession in each database, this ID mapping file creates a useful look up 
table used to retrieve data from each of these databases. The identifiers represented on 
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this array were as follows: 6% UniProtKB, 55% RefSeq, 10% Ensembl, 1% Entrez Gene, 
1% BROAD, and 27% ESTs [Figure 3.3].  From the small percentage of UniProtKB in 
comparison to the larger percentage of the RefSeq and ESTs, we can see that high-quality 
information linked to this array is limited. With the highest quality annotations being 
UniProtKB, this initial mapping indicates a need for re-mapping and re-annotation with 
the purpose of increasing the percentage of UniProtKB accessions. For example, the 
majority of mapping is to RefSeq accessions. Of those 15,024 accessions, less than 1% of 
the identifiers mapped to known proteins, designated NP. The remaining accessions were 
mapped to predicted proteins, designated XP. Thus, less than 1% of those RefSeq 
accessions have undergone manual biocuration to confirm or deny their predicted 
function. 
 
Figure 3.3 Breakdown of identifier types before and after re-mapping. 
The increase in the number of UniProtKB indicates that the quality of the annotations 
retrieved for the new ID mapping file will also increase. 
After re-mapping, the probeset identifiers from the array were linked to a total of 
29,909 unique identifiers and accessions. This increase in the number of identifiers 
associated with this array is due to probeset identifiers mapping to more than one 
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identifier. The new breakdown of identifier types represented is as follows: 22% 
UniProtKB, 50% RefSeq, less than 3% Ensembl, 1% BROAD, and 24% ESTs [Figure 
3.3]. As indicated previously, the higher the number of UniProtKB accessions, the higher 
the quality of total annotations associated with the array.  UniProtKB accessions are the 
highest quality identifiers because of the biocuration the identifiers must undergo and the 
comprehensive nature of information linked to the identifiers. Although the majority of 
identifiers once again mapped to RefSeq accessions, as a result of the re-mapping, there 
was a marked improvement in the quality of annotations to be retrieved based on the 
increase in the percentage of UniProtKB identifiers. The complete results can be found at 
the AgBase website.  
In the original annotation file (released in 2006), the Affymetrix annotation file 
provided with the canine array linked the probesets with 15,822 GO annotations for 2,608 
gene products represented on the array. After re-mapping these identifiers, we linked the 
updated probeset with 10,737 GO annotations representing 5,127 gene products. This 
decrease in the amount of GO annotations is partly due to the new set of gene products 
associated with the array and partly because of revisions to the GO annotations (as 
functional annotations are improved, some previous annotation may be deleted or 
revised). Since our remapping of the array probesets decreased the initial functional 
annotation associated with these gene products, we next provided additional GO 
annotation for these gene products. 
Since the EBI GOA Project provides GO annotations for UniprotKB proteins and 
AgBase biocurators provide GO annotation for Genbank(RefSeq) proteins with no 
equivalent UniProtKB entry, we found that there were already 41,155 existing GO 
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annotations for UniProtKB accessions and 69,821 existing GO annotations for 
Genbank(RefSeq) proteins. Moreover, AgBase biocurators manually added detailed, 
experimental base GO annotations from published papers, providing another 321 GO 
annotations for 44 gene products (this work is ongoing). Since 98% of the 
Genbank(RefSeq) proteins are designated as “XP” or “unknown proteins” (that is, there 
is no direct evidence that these proteins are translated, but rather they are predicted based 
on EST and homology to other known mammalian proteins), it is unlikely that these 
proteins will have any direct experimental evidence as to their function. Thus, we focus 
our manual biocuration on the 1053 UniProtKB proteins that currently have no GO and 
the 97 “known” Genbank(RefSeq) proteins (designated with “NP” prefix). 
Likewise, EST sequences also have no functional literature. However, because 
ESTs are typically short sequences, they cannot be reliably linked to orthologous genes in 
other species. Providing a first pass functional annotation for these sequences requires an 
analysis of functional motifs and domains to identify sequences with conserved function 
[9]. Using this approach, we provided 22,006 annotations for 7,291 ESTs on the array 
that had no equivalent mRNA or proteins sequence. However, 99.2% of the gene 
products were annotated as ND or “no data”. While this may be considered as a “null” 
result, it does alert researchers to the fact that there is currently no functional data 
available for these transcripts; further functional classification must await improved 
sequence annotation. However, these initial GO annotations can be added to the AgBase 




Overall, we added 70,148 GO annotations for 16,966 gene products. This 
represents an increase from an initial 14% of the gene products represented on the array 
associated with functional annotation to 94% of the gene products represented on this 
array having some GO annotations. This represents almost a seven-fold increase in the 
number of gene products than were initially annotated [Figure 3.4]. Moreover, analysis of 
the GO quality (using the AgBase GAQ Score tool) mirrors this data in indicating an 
increase in quality of mean GAQ score from the initial 87.4% to 90.4%. 
 
Figure 3.4 Gene products represented on the array that are linked to GO annotation. 
Of the 18,000 gene products represented, the original annotation file available with the 
Affymetrix GeneChip® Canine Genome 2.0 microarray only provided GO annotations 
for 14% of the entire array. After re-mapping and re-annotation, we have provided GO 
annotations for 94% of all gene products represented on this array. 
Conclusion 
By re-analyzing and updating the annotation data associated with the Affy canine 
array we were able to provide a comprehensive list of public database accessions that the 
probes represent and to associate these gene products with GO annotation to facilitate 
functional modeling. In doing so, we have not only updated the canine gene products 
 
29 
represented on the array to reflect the newest genome release, but we have also improved 
the functional annotation linked with these products by almost seven-fold. Since 95% of 
the canine datasets produced from this array (and submitted to GEO as of 2/2013) remain 
unpublished, our goal is to facilitate functional modeling of data produced by this and 
other canine arrays. By making this data publicly available we expect to facilitate the use 
of canine functional genomic data to provide insights into canine biology, rather than to 
generate long lists of transcripts. With the advent of new sequencing technologies that are 
producing even larger and more complex transcriptome data sets, it is becoming 
increasingly important that functional annotation is provided for those gene products 
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USE OF LIPOSOMAL CLODRONATE (LC) TO FACILITATE DETECTION OF 
SUBCLINICAL INFECTION WITH BABESIA CANIS IN POTENTIAL  
BLOOD DONOR GREYHOUNDS 
Background 
An emerging disease in the U.S., babesiosis has become a particular problem in 
greyhound kennels. As greyhounds, often retired from the racetrack, are the most 
common breed to be used as blood donors, babesiosis has a critical impact on the use of 
blood donors in veterinary medicine [3]. In greyhounds, babesiosis is most commonly 
associated with Babesia canis vogeli, a protozoan parasite of red blood cells (RBCs) that 
is carried by the brown dog tick, Rhipicephalus sanguineus [1]. It is thought to take 2-3 
days of attachment by the tick for transmission of the sporozoite stages of the organism to 
occur [4]. 
Although babesiosis is usually subclinical in greyhounds, it can cause serious 
illness, even fatalities, in dogs inadvertently transfused with infected blood [5, 6]. 
Identification of donors with occult Babesia infection is therefore essential for 
transfusion safety. Techniques utilized to detect the presence of Babesia include direct 
microscopic observance of blood smears, IFA (indirect fluorescent antibody) serology, 
PCR (polymerase chain reaction) [2, 6], and counting infected cells using a laser-based 
cell counter such as flow cytometry [7, 8]. Each method has its own draw backs. For 
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example, the blood smear depends on active parasitemia, but in greyhounds the infection 
is commonly subclinical with animals being chronic carriers [6]. The organism therefore 
might not show up when using only direct microscopy. This is also a draw back with 
detection via flow cytometry. When running antibody tests, it is hard to prove whether a 
positive test is the result of a current infection or an infection already cleared by the 
host’s immune system. PCR, on the other hand, is a definitive test for Babesia infection, 
but it is not a technique that most clinics have readily available. It does not allow for 
quantitation of the number of infected RBCs. 
In the past, deciding whether or not an animal could become a blood donor was as 
easy as surgically removing the spleen. Since the spleen is required to help fight infection 
with blood-borne pathogens, splenectomy would allow for a flare-up of any blood borne 
parasite.  This highly invasive procedure is no longer recommended, and an alternative is 
needed. In this study, we sought to evaluate the use of liposomal clodronate (LC) to 
facilitate the detection of subclinical infection with Babesia canis in potential blood 
donor greyhounds. 
Liposomal clodronate has been shown to deplete macrophages and monocytes by 
induction of apoptosis via lysis of the mitochondrial membrane [9,10]. This results in an 
overall transient immune suppression that loses effect when the drug is no longer present 
in therapeutic levels. Since macrophages are needed to recognize and remove Babesia-
infected RBCs from circulation, it has been proposed that LC may ‘unveil’ hidden 
babesiosis in infected greyhounds. The main objective of this study was to determine if 
LC would reveal any sequestered organisms in dogs with a history of exposure to 





Four healthy Babesia canis-exposed adult greyhounds and one Walker hound 
(used as a non-treated control) was used for this study. Health was confirmed based on 
physical examination, blood smear, complete blood count (CBC), serum biochemistry, 
and urinalysis. The greyhounds had a history of being variably positive for Babesia canis 
infection: one was IFA negative/PCR low positive, another was IFA and PCR negative 
but came from the same source as the other affected dogs and was housed and transported 
with them, another was IFA positive/ PCR high positive, and a final dog was IFA 
negative/ PCR positive. Greyhound results also varied between IFA/PCR testing dates. 
At the time of administration of LC, all dogs had become negative on every test for 
Babesia canis for at least three months. All animals were cared for according to 
guidelines approved by the Mississippi State University Institutional Animal Care and 
Use Committee (IACUC), and were housed in a university setting under standard 
conditions. The Mississippi State University animal facilities and program are accredited 
by the American Association for Accreditation of Laboratory Animal Care.  
Treatment 
Liposome clodronate (LC) (dichloromethylenedisphosphonic acid disodium salt, 
SIGMA, encapsulated into liposomes at Colorado State University) was administered to 
four greyhounds at low (0.5 ml/kg), medium (1 ml/kg), and high (2 ml/kg) doses via slow 
intravenous infusion at a constant rate into an indwelling peripheral venous catheter over 




A schematic of the study design is shown in Figure 4.1. Briefly, the study began 
with baseline monitoring for levels of infected RBCs in greyhounds prior to treatment 
with LC and subsequent assessment of levels of infected RBCs in LC-treated dogs 
(Figure 4.1).  
 
Figure 4.1 LC treatment timeline. 
Arrows L (yellow), M (blue), H (red) indicate the low, medium, and high dose 
treatments. Each dash indicates a RBC assessment time point (three times a week).  
(D)  represents the number of RBC assessment time points in the study. 
Reagents 
BD Pharm Lyse™ (10X) lysing solution (BD Biosciences) was used to remove 
red blood cells from the white blood samples collected in EDTA tubes. Hydroethidine 
(HE) or dihydroethidium (Invitrogen D1168) in DMSO (Sigma D2650) at 1:2000 was 
used to stain any nuclear components within RBCs for analysis by flow cytometry. 
Cell Preparation 
White Blood Cells (as positive controls) 
To remove red blood cells (RBCs), whole blood samples collected in EDTA were 
incubated with BD Pharm Lyse ™ lysing buffer for 15 minutes in the dark at room 
temperature, gently vortexing every 5 minutes. The remaining cell populations were 
washed, incubated with a 1:2000 hydroethidine solution for 30 minutes at 37°C, then 
were washed and analyzed by flow cytometry. 
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Red Blood Cells  
Whole blood samples collected in EDTA were washed and buffy coats were 
discarded. RBCs were incubated with a 1:2000 hydroethidine solution for 30 minutes at 
37° C, then were washed and the level of HE inclusion was analyzed by flow cytometry. 
Flow Cytometry 
Canine RBCs were gated based on their relative size and granularity using 
forward and side scatters (FSC and SSC, respectively) with FACSCalibur Flow 
Cytometer (Becton Dickinson). Data were analyzed using FlowJo 7.6.4 Software (Tree 
Star, Inc.). The staining resulting from inclusion of HE into the RBC was analyzed by 




Figure 4.2 Assessment of RBCs exhibiting HE inclusion by flow cytometry. 
Canine red blood cells were gated using forward and side scatters (A). RBCs stained by 
inclusion of HE into the nuclei were analyzed by using single color histogram statistics 
(B-negative control; C-experimental sample). 
Statistical Analysis 
RBCs exhibiting inclusion of HE as a specific population was expressed as a 
percentage of the total RBC numbers. Then, data was subjected to a one-way analysis of 
variance (ANOVA) followed by Fisher’s LSD multiple comparison post hoc test and are 




Results and Discussion 
Many canine vector-borne diseases can cause serious, even life-threatening 
clinical conditions in dogs, with a number also having significant zoonotic potential and 
affecting human populations [1, 11]. Since greyhounds are one of the most common 
breeds utilized as blood donors in veterinary medicine, accurate and efficient detection of 
canine vector borne diseases such as babesiosis is essential for preventing potentially 
devastating transfusions of infected blood. Here we used flow cytometry to determine the 
level of Babesia canis infection in greyhounds treated with LC.  
Consistent baseline negative status on assays for Babesia upon repeat testing was 
confirmed over a 2 week period by a single IFA,flow cytometry and PCR approximately 
every second day and daily smear examination (data not shown). Flow cytometry and 
blood smear examinations (modified Wright’s stain) were performed at MSU, and 
serology (IFA) and PCR were performed at the North Carolina State University (NCSU) 
Vector Borne Disease Diagnostic Laboratory. The 4 greyhounds were then given 
intravenous liposomal clodronate at a single low dose of 0.5 ml/kg.  Babesia status was 
monitored over a 2 week period post-treatment by daily smear examination, and by flow 
cytometry and PCR approximately every second day. The same study design was then 
repeated at a medium liposomal clodronate dose of 1 ml/kg and then, finally, at a high 
liposomal clodronate dose of 2 ml/kg except that, after the final dose of liposomal 
clodronate, Babesia status was monitored for an extended post-treatment period of 4 
weeks by daily smear examination, by flow cytometry and PCR every second day, and by 
repeat serology. There were minor numerical non-significant increases in the numbers of 
HE+  RBCs at various time points in greyhounds exposed to all three doses of LC (Figure 
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4.3). Interestingly, a marked increase in the numbers of HE+ RBCs was found in an 
unrelated canine patient with increased numbers of reticulocytes by CBC (Figure 4.4) 
suggesting that the LC-related increases in greyhounds could be due to increased 
numbers of reticulocytes, although daily CBCs performed on the 4 greyhounds did not 
support this speculation. Based on lack of evidence of Babesia infection by blood smear 
examination, PCR or serology at any point during the study period (data not shown), we 
conclude that LC does not appear to be a reliable means of exposing occult babesiosis in 
greyhounds with a recent history of harboring the organism. To investigate if the 
numerical non-significant increases in HE+ RBCs numbers were due to the effect of LC, 
RBCs from 3 healthy Walker hounds (see Methods, Chapter 5) exposed to the medium 
dose of LC were assessed by flow cytometric analysis. There were no significant 
differences in the numbers of HE+ RBCs in the LC-treated animals compared to the non-
treated controls (data not shown) suggesting that the observed numerical increases in the 




Figure 4.3 Effect of LC exposure on numbers of RBCs exhibiting inclusion of HE in 
greyhounds in Babesia canis-exposed greyhounds. 
RBCs from 4 healthy but Babesia-exposed greyhounds treated with low (0.5 ml/kg), 
medium (1 ml/kg), and high (2ml/kg) doses of LC were assessed by single color flow 
cytometry approach. Data are expressed as a mean % of total RBCs. No statistical 
significance indicated. 
 
Figure 4.4 Flow cytometric analysis of RBC HE incorporation in the canine clinical 
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SELECTIVE LC-DEPENDENT REMOVAL OF PROFESSIONAL ANTIGEN 
PRESENTING CELLS, MONOCYTES/MACROPHAGES, AND  
IMMATURE DENDRITIC CELLS PROMOTES INCREASES 
 IN CD4+CD25+FOXP3+ REGULATORY T CELLS 
Abstract 
A critical component of host immune systems, regulatory T cells (Tregs) have 
been described in detail in humans and mice. Although some researchers have begun to 
study canine Tregs, comprehensive functional information has not yet been produced. We 
evaluated the effect of depletion of professional antigen presenting cells (APCs) on the 
levels and phenotypes of regulatory T cells (Tregs) in dogs treated with liposomal 
clodronate (LC) by multi-color flow cytometric analysis. We demonstrate that numbers 
of Tregs increased after administration of various LC doses in greyhounds, and the same 
effect was found in Walker hounds by using the medium LC dose. Our study shows a 
correlation between levels of CD14+ monocytes and Tregs in dogs treated with LC. These 
data demonstrate that, as in humans, the population of CD4+CD25high T cells most 
reliably identified as the highly enriched FOXP3+ Tregs in dogs. In addition, we defined 
the CD4+CD25lowFOXP3+ cells as the major regulatory T cell subset affected by LC 





An important aspect of the host immune system, regulatory T cells (Tregs) are a 
known CD4+CD25+FOXP3+ subset of T cells which are responsible for maintaining 
tolerance by suppression of natural immune responses [1]. These cells have been proven 
to develop normally, and they can also be induced to develop as antigen specific Tregs 
from conventional peripheral CD4+ T cells [2].  
Although there is very little known about the functional significance of regulatory 
T cells in the canine, Tregs are an important constituent of healthy function in the host 
immune system. In normal systems when activated or increased in numbers to a suitable 
concentration, Tregs can help to prevent autoimmune dysfunction of the host [3], or they 
may only exacerbate a current problem [4]. Although more research is needed, studies 
have shown that FOXP3 (forkhead box P3 transcription factor) is necessary for the 
generation of naïve T cells into regulatory T cells with suppressive functions. Without 
FOXP3, the recognizable immunosuppressive function can be lost [5]. 
Monocytes and macrophages are professional antigen presenting cells (APCs) that 
express multiple phagocytic and signaling pattern recognition receptors (PRRs) that sense 
and bind pathogen-associated molecular patterns (PAMPs) and produce cytokines [6,7,8]. 
Recent studies show that monocytes and macrophages are not limited to presenting 
antigens to effector T cells and stimulating and shaping T cell-mediated immune 
responses; they also prime naïve T cells, thus initiating adaptive immune responses 
[6,7,8,9,10]. 
Liposomes have been proven to increase the effectiveness of certain drugs by 
being used as drug carriers and allowing the liposome to follow its natural course, 
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undergoing phagocytosis. Clodronate (dichloromethylene bisphosphate), a small 
hydrophilic molecule which functions to induce apoptosis via lysis of the mitochondrial 
membrane of host monocytes, dendritic cells, and macrophages, is one such drug [11]. 
The overall effect on the immune system of administering liposomal clodronate is a 
transient immune suppression which may be either detrimental or helpful to the host. It 
can be seen in the depletion of the number of viable circulating monocytes and 
macrophages [12]. Liposome encapsulated clodronate (liposomal clodronate, LC) is 
currently being used in research in a variety of approaches that include: to selectively 
deplete monocytes and macrophages to provide controls for evaluating muscle injury 
[13]; to prove the role of the immune cells in dengue fever [14]; to accelerate alveolar 
macrophage reconstitution [15]; to decrease dissemination and brain invasion of 
Cryptococcus neoformans;[16], and to treat diseases such as gout and various 
autoimmune diseases [17].  
Current researchers in canine immunology utilize the specialized depletion tactics 
made possible by LC, but have also begun to explore the unknown concerning regulatory 
T cells. 
In the current study, we assessed the levels and phenotypes of 
CD4+CD25+FOXP3+ regulatory T cells in greyhounds and Walker hounds treated with 
different doses of LC. 
Materials and Methods 
Dogs 
Healthy adult greyhounds and Walker hounds were used for this study. Health 
was confirmed based on physical examination, complete blood count (CBC), serum 
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biochemistry, and urinalysis. CBC and serum biochemistry were completed by the 
Mississippi State University College of Veterinary Medicine Diagnostic Laboratory 
Services (CVM-DLS).All animals were cared for according to guidelines approved by the 
Mississippi State University Institutional Animal Care and Use Committee (IACUC), and 
were housed in a university setting under standard conditions. The Mississippi State 
University animal facilities and program are accredited by the American Association for 
Accreditation of Laboratory Animal Care. 
Treatment 
Liposome clodronate (LC) (dichloromethylenedisphosphonic acid disodium salt, 
SIGMA, encapsulated into liposomes at Colorado State University) was administered to 
four greyhounds at low (0.5 ml/kg), medium (1 ml/kg), and high (2 ml/kg) doses via slow 
intravenous infusion at a constant rate into an indwelling peripheral venous catheter over 
a 90-minute period, using an infusion pump. 
In the Walker hound study, LC (Encapsula NanoSciences in Nashville, TN) was 
administered to three Walker hounds as previously described at a single dose of 1 ml/kg. 
In both studies, control dogs received no treatment. 
Study Design 
The design of the greyhound study is shown in Figure 5.1. Briefly, the study was 
divided into baseline monitoring of Tregs in greyhounds prior to their treatment with 
different doses of LC and the assessment of levels of regulatory T cells in LC-treated 
dogs (Figure 5.1). Similarly to the greyhound study, the Walker hound study consisted of 
the baseline and after the treatment monitoring of Tregs. However, the experimental 
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animals were exposed only to the medium dose of LC, and their peripheral blood 
monocytes levels as well as total cell blood counts were determined in addition to Tregs. 
 
Figure 5.1 LC treatment timeline. 
Arrows L, M, H indicate the low, medium, and high dose treatments. The dashes indicate 
Treg assessment time points. (D-0/25/13) represents the number of assessment time 
points in the study. (A) represents the greyhound study. (B) represents the Walker hound 
study. 
Reagents and Antibodies 
BD Pharm Lyse™ (10X) lysing solution (BD Biosciences) was used to remove 
red blood cells from the white blood samples collected in EDTA tubes. 
Fluorescein -conjugated mouse anti-canine CD14 mAbs (LS-C43762, Lifespan 
Biosciences, Inc.) were used to stain monocytes. Fluorescein -conjugated rat anti-canine 
CD4 (LS-C127352, Lifespan Biosciences, Inc), Phycoerythrin (PE)-conjugated mouse 
anti-canine CD25 (P4A10) and the FOXP3 Staining Buffer Set (including 
Fixation/Permeabilization Diluent, Fixation/Permeabilization Concentrate, 10X 
Permeabilization Buffer) and allophycocyanin (APC)-conjugated rat anti-canine FOXP3 





Whole blood samples collected in EDTA were incubated with Fluorescein-
conjugated anti-CD14 mAbs for 30 minutes in the dark at 4°C. To lyse and remove red 
blood cells, samples were incubated with BD Pharm Lyse ™ lysing buffer for 15 minutes 
in the dark at room temperature, gently vortexing every 5 minutes. The resulting cell 
populations were washed and analyzed by flow cytometry. 
Regulatory T cells 
Whole blood samples collected in EDTA were incubated with Fluorescein-
conjugated anti-CD4 and PE-conjugated anti-CD25 mAbs for 30 minutes in the dark at 
4°C. To remove red blood cells, samples were incubated with BD Pharm Lyse ™ lysing 
buffer for 15 minutes in the dark at room temperature, gently vortexing every 5 minutes. 
Red blood cells were removed, and the remaining cell populations were washed and 
stained with anti-FOXP3 staining buffer set following the manufacturer’s instructions. 
Briefly, cells were incubated with fixation/permeabilization solution for 30 minutes in the 
dark at 4°C, washed twice with permeabilization buffer followed by incubation with 
APC-conjugated anti-FOXP3 mAbs for 30 minutes in the dark at 4°C. After a single 
wash, cells were then analyzed by flow cytometry. 
Flow Cytometry 
Red blood cell depleted canine cells were gated based on their relative size and 
granularity using forward and side scatters (FSC and SSC, respectively) with 
FACSCalibur Flow Cytometer (Becton Dickinson). Immunofluorescent stainings were 
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analyzed using FlowJo 7.6.4 Software (Tree Star, Inc.). The CD14 immunofluorescent 
staining in canine monocytes was analyzed by using single histogram statistics (Figure 
5.2). A three-color analysis was performed to assess the FOXP3 staining by gating on 
CD4+CD25+ double positive T cells and analyzed by using single histogram statistics 
(Figure 5.3). In addition, the intensity of the CD25 fluorescence in the CD4+FOXP3+ 
cells was assessed by using dot plots with multiple gate statistics (Figure 5.4). 
 
Figure 5.2 Assessment of CD14+ monocytes by flow cytometry. 
RBC- depleted canine cells were gated based on their relative size and granularity using 
forward and side scatters (A). The CD14 immunofluorescent staining in canine 




Figure 5.3 Identification of CD4+CD25+FOXP3+ regulatory T cells by three color 
flow cytometry approach. 
RBC- depleted canine cells were gated based on their relative size and granularity using 
forward and side scatters (A). Two color analysis for the CD4+CD25+ T cells was 
performed by using dot plots with quadrant statisics (B). The FOXP3 staining intensity 




Figure 5.4 FOXP3 expression in peripheral blood of CD25low, CD25medium, and 
CD25high CD4+ T cells. 
The CD4+ T cells were gated based on the brightness of CD25 staining (A). FOXP3 
histograms of T cells of low, medium, and high CD25 fluorescence intensity (B,C,D, 
respectively). 
Statistical Analysis 
Regulatory T cell marker-specific populations were expressed as a percentage of 
the total lymphocyte numbers or as absolute cell numbers. CD14+ monocyte populations 
were expressed as a percentage of PBMC. Then, data was subjected to a one-way 
analysis of variance (ANOVA) followed by Fisher’s LSD multiple comparison post hoc 
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test and are presented as means + SD. The level of significance for all tests of effects was 
set at P<0.05. 
Results 
Liposomal clodronate exposure promotes increases in the levels of 
CD4+CD25+FOXP3+ regulatory T cells in greyhounds 
To characterize effects of the monocyte depletion on the levels of Tregs in dogs, 
we treated 4 healthy greyhounds with different doses of LC and assessed the levels of 
peripheral blood Tregs by flow cytometry. Percentage of CD4+CD25+FOXP3+ Tregs 
significantly increased in greyhounds treated with low and medium doses of LC (Figure 
5.5). Although the percentage of Tregs in dogs treated with high dose of LC increased, 
these increases were non-significant (Figure 5.5). 
 
Figure 5.5 LC exposure promotes increases in regulatory T cell populations in dogs. 
Regulatory T cells from 4 healthy greyhounds exposed to low (0.5 ml/kg), medium (1 
ml/kg), and high (2 ml/kg) doses of LC were assessed by three color flow cytometry 




Effects of LC treatment on the peripheral blood regulatory T cell and monocyte 
fluctuations in Walker hounds 
To further investigate possible mechanisms of LC-dependent regulatory T cell 
fluctuations, we assessed the levels of CD4+CD25+FOXP3+ Tregs and CD14+ monocytes 
in Walker hounds challenged with medium dose LC. As expected, LC treatment 
promoted decreases in CD14+ monocyte numbers in all experimental dogs after 24hrs of 
treatment, followed by significant increases during compensatory period (4-7 days post 
treatment) and declining to initial baseline levels after 8-11 days of LC challenge (Figure 
5.6, C). In general, the LC-dependent Tregs fluctuations were similar to the changes in 
the levels of CD14+ monocytes. However in contrast to the monocyte levels, the 
percentage of Tregs after 24hrs of treatment showed only slight non-significant decrease 
(Figure 5.6, A). Next, we evaluated the absolute numbers of Tregs in the peripheral blood 
of Walker hounds before and after LC treatment. Figure 5.6, B demonstrates a significant 
decrease in the Treg numbers after 24hrs of LC treatment, an expected compensatory 




Figure 5.6 Effects of LC treatment on the levels of CD4+CD25+FOXP3+ regulatory T 
cells and CD14+ monocytes in peripheral blood of Walker hounds. 
Regulatory T cells and monocytes from 3 healthy dogs exposed to medium dose of LC (1 
ml/kg) were assessed by three and one color flow cytometry analysis, respectively. (A) % 
Tregs of total lymphocytes; (B) absolute numbers of Tregs; (C) % monocytes of total 
PBMC; (1) Baseline levels[prior to treatment]; (2) Initial response to LC [24 hours post 
treatment]; (3) Compensatory response to LC [4-7 days post treatment]; (4) 
Normalization [8-11 days post treatment]. Data are expressed as a mean % of total 
PBMC (A,C) or as mean absolute cell counts (B). (a b *) indicates group differences 
(P<0.005). 
CD4+CD25lowFOXP3+ are the major regulatory T cell subset affected by LC 
exposure 
Previously reported data in humans demonstrated that although CD4+CD25+ T 
cells contain Tregs, other cells such as recently activated pathogenic T cells may also fall 
in this phenotypic subset [29]. The top 2% CD4+CD25bright T cells most reliably 
identified a highly enriched FOXP3+ Tregs.  To identify the population of Tregs 
selectively targeted by LC we applied multiple gate statistics for the assessment of CD25 
fluorescence intensity in CD4+CD25+FOXP3+ T cells (Figure 5.7). There was a 
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numerical decline in % of Tregs expressing low, medium and high levels of CD25 two 
days after treatment, followed by an increase, which was significant only in 
CD4+CD25low FOXP3+ Tregs. The levels of Tregs in all three populations with 
differential expression of CD25 after two weeks of LC exposure were comparable with 
their levels prior to the LC treatment. 
 
Figure 5.7 LC exposure promotes significant increases in the most recently activated 
CD4+CD25lowFOXP3+ Tregs. 
CD4+FOXP3+ T cells from the dogs exposed to LC were gated based on brightness of 
CD25 staining resulting in separation into low, medium, and high expressers of CD25. 
(1) Baseline levels [prior to treatment]; (2) Initial response to LC [24 hours post 
treatment]; (3) Compensatory response to LC [4-7 days post treatment]; (4) 
Normalization [8-11 days post treatment]. Data are expressed as mean % of total Tregs. 
(a b) indicates group differences. 
Discussion 
Adequately described in humans and mice, regulatory T cells 
(CD4+CD25+FOXP3+ T cells) are an essential requirement for the healthy function of the 
mammalian immune system as they function to modify or inhibit effector cells. This 
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makes them a double edged sword. When functioning properly, they help to maintain 
homeostasis within the immune response, but if malfunctioning or absent, they can 
impede beneficial immune responses, and systemic and/or organ-specific autoimmunity 
can result [19]. 
Little is known about the functional purpose and clinical relevance of Tregs in 
canines, but results from recent studies have provided initial phenotypic and functional 
characterizations of Tregs within the canine system [20, 21, 22]. Current research 
objectives include understanding Tregs across a wide range of disease models. The 
results of current studies indicate that increased numbers of Tregs are associated with 
disease consequence [22, 23, 24, 25, 26, 27]. This study expands previous research to 
include new breeds of healthy dogs, while observing variation between numbers of Tregs 
in greyhounds and Walker hounds. 
In the current study, the overall effect of the differing doses of LC on the 
experimental dogs was assessed during the greyhound study. As previously mentioned, 
LC has many uses in the treatment of autoimmune diseases as well as research [13, 14, 
15, 16, 17, 18]. The goal in using LC was to transiently knock out the immune system by 
initiating a period of monocyte/macrophage/DC depletion, thus allowing us to evaluate 
the levels of decrease or generation of regulatory T cells over the defined treatment 
period.  
For each dog, a similar pattern was observed in the levels of Tregs in response to 
each dose (low, medium, high). The overall health of the dogs also varied. At the low and 
medium dose, no clinical signs or negative effects were witnessed in the dogs. While at 
the high dose, dogs developed clinical signs including transient fever, diarrhea, clear 
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nasal discharge, and general malaise. To this end, the medium dose (1 mg/kg) was chosen 
to be utilized in the Walker hound study. This dose allowed resultant changes in Treg 
levels to be observed while avoiding the development of clinical signs.  
For the first time, this study evaluated numbers of canine regulatory T cells in the 
absence of professional antigen presenting cells (APCs), monocytes, and immature DCs 
by utilizing LC. In the greyhound study, the number of Tregs after a visible profound 
decline (during the initial response phase, 24 hrs post treatment) significantly increased 
when dogs were treated with the low and medium dose, and while the high dose also 
resulted in increase in Tregs, no significance was observed. 
The relationships between monocytes/macrophages and Tregs within the canine 
model are unknown. Recent studies have expanded the role of monocytes and 
macrophages beyond presenting antigens to effector T cells and stimulating T cell 
mediated immune responses. They also are responsible for initiating adaptive immunity 
via priming of naïve T cells, triggering the generation of new Tregs, a critical subset of T 
cells [6,7,8]. Therefore, in the Walker hound study, both monocyte and Treg numbers 
were assessed simultaneously. The significant decreases in monocyte numbers in all 
experimental dogs 24 hrs after treatment was expected and reflects the expected 
mechanism of action of LC. When the bisphosphonate clodronate is incorporated within 
liposomes, phagocytosis by monocytes/macrophages and immature DCs is enhanced 
[28]. Lysis of the mitochondrial membrane of host cells by LC induces apoptosis 
resulting in the transient depletion of monocytes [11]. At the same time, absolute Treg 
numbers were also evaluated showing significant compensatory gains as well as the 
significant recovery of Treg numbers during the normalization period. In theory, these 
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compensatory gains reflect initiation of adaptive immune response by production of new 
Tregs via activation from naïve T cells in the periphery.  
As a part of the Walker hound study, we produced data that mirrors information 
reported in human Tregs that, although canine CD4+CD25+ T cells contain Tregs, other 
cells such as recently activated pathogenic T cells may also fall in this phenotypic subset. 
The top 2% CD4+CD25bright T cells most reliably identified a highly enriched FOXP3+ 
Tregs in dogs. We report that CD4+CD25lowFOXP3+ is the major regulatory T cell subset 
affected by LC exposure, showing the significantly increased numbers after 4-7 days of 
LC-treatment. These increases suggest the active recruitment and generation of Tregs 
from naïve CD4+ peripheral blood T cells. 
In conclusion, further research is essential in creating a working understanding of 
canine CD4+CD25+FOXP3+ Tregs, and the role of professional APCs monocytes and 
DCs in their generation. Tregs are a critical subset of immune cells which are produced 
during T cell development in the thymus and can be induced in the periphery from naïve 
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